Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $2.54 million. The enterprise value is -$3.91 million.
Important Dates
The next estimated earnings date is Friday, May 9, 2025, after market close.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 905,228 shares outstanding. The number of shares has increased by 1,103.92% in one year.
| Current Share Class | 905,228 |
| Shares Outstanding | 905,228 |
| Shares Change (YoY) | +1,103.92% |
| Shares Change (QoQ) | +106.87% |
| Owned by Insiders (%) | 5.09% |
| Owned by Institutions (%) | 3.52% |
| Float | 859,183 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.32 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43
| Current Ratio | 3.43 |
| Quick Ratio | 3.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -264.85% and return on invested capital (ROIC) is -87.78%.
| Return on Equity (ROE) | -264.85% |
| Return on Assets (ROA) | -52.93% |
| Return on Invested Capital (ROIC) | -87.78% |
| Return on Capital Employed (ROCE) | -169.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.67M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.37% in the last 52 weeks. The beta is 0.24, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -91.37% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 11.04 |
| Relative Strength Index (RSI) | 44.34 |
| Average Volume (20 Days) | 146,324 |
Short Selling Information
The latest short interest is 51,318, so 5.67% of the outstanding shares have been sold short.
| Short Interest | 51,318 |
| Short Previous Month | 23,472 |
| Short % of Shares Out | 5.67% |
| Short % of Float | 5.97% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.98M |
| Pretax Income | -15.90M |
| Net Income | -15.04M |
| EBITDA | -7.95M |
| EBIT | -7.98M |
| Earnings Per Share (EPS) | -$87.68 |
Full Income StatementBalance Sheet
The company has $6.50 million in cash and n/a in debt, giving a net cash position of $6.50 million or $7.18 per share.
| Cash & Cash Equivalents | 6.50M |
| Total Debt | n/a |
| Net Cash | 6.50M |
| Net Cash Per Share | $7.18 |
| Equity (Book Value) | 4.71M |
| Book Value Per Share | 9.02 |
| Working Capital | 4.65M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.32 million and capital expenditures -$19,171, giving a free cash flow of -$18.34 million.
| Operating Cash Flow | -18.32M |
| Capital Expenditures | -19,171 |
| Free Cash Flow | -18.34M |
| FCF Per Share | -$20.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |